All News

The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.

Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will benefit from intensified treatment.

I was diagnosed with breast cancer, then lung cancer 17 years later — and both ultimately led me to make meaningful, positive changes in my life.

A patient on the Monjuvi trial saw lymph nodes shrink 85%, with stable results a year later, supporting the FDA’s recent approval for follicular lymphoma.

Thirteen years after cervical cancer, I’ve found strength in healing, grief in silence, and hope in sharing the quiet truths of survivorship.

Five years after my lymphoma diagnosis, life looks normal on the outside; however, the fear of recurrence and the reality of cancer never fully fade.

Dr. Alexandra Zaleta discussed actionable steps that individuals can take to advocate for a more person-centered insurance practice approach.

The FDA granted fast track designation to TRE-515 plus radioligand therapy for treating PSMA-positive metastatic castration-resistant prostate cancer.

Survivors can find strength after cancer by focusing on goals, loved ones, and spiritual connection, especially during challenging or uncertain times.

I found a lump and was shocked to learn it was breast cancer, but over 22 years I’ve learned healing takes time, asking for help is strength, and hope grows.

Bob Lane discusses his experience with prostate cancer, and describes what survivorship and cure means to him as someone living with metastatic disease.

Patients with nonmetastatic prostate cancer treated according to NCCN Guidelines are more likely to die of other natural causes than from their cancer.

After nearly 11 years of living with Hodgkin lymphoma, my sister Kathleen passed away peacefully at 39, leaving me to navigate the sorrow of losing her.

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic castration-sensitive prostate cancer.

The U.S. FDA has approved a new test for patients with lung cancer to match the correct individuals with a targeted treatment called Zegfrovy.

Olalekan O. Oluwole discusses how CAR T-cell therapy is used to treat high-risk hematologic malignancies like lymphoma and leukemia.

Breast cancer care differs around the world, revealing urgent unmet needs in Nepal, where access, support, and treatment remain out of reach for many.

Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses; however, molecular testing can help guides treatment decisions.

Daniel Jernazian, a two-time cancer survivor, shares how sports, advocacy and meeting his idol shaped his journey through illness and recovery.

I celebrated five years since my bone marrow transplant with a surprise video from my donor, a beautiful reminder of the life she helped me keep.

Dr. Alicia Arnold and Dr. Priyanka Raval discuss first- and later-line treatment options for those with ER-positive, HER2-negative stage 4 breast cancer.

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and cancer-related bone conditions.

Mark Daniels, an 83-year-old veteran and former fighter pilot, was shocked by his lymphoma diagnosis because he maintained exceptional physical fitness.

After eleven 11 of survivorship, I’ve been waiting to hear the words, “You’re completely free of cancer! Go in peace,” but I’m wondering if it ever will happen.

Ongoing research within the advanced-stage melanoma therapeutic space is beginning to suggest that shorter treatment periods may be sufficient for some.

Valarie Traynham sat down for an interview in CURE in which she discussed adjusting to life after cancer, detailing her ‘new normal.’

Dr. Alexandra Zaleta discussed the impact of administrative delays and insurance red tape experienced by patients with advanced cancer.

My cancer journey taught me that nothing is certain; however, with support, humor and acceptance, we can weather the ups and downs.

In a phase 2 study, 52% of patients treated with Bria-IMT plus a checkpoint inhibitor for metastatic breast cancer were alive at one year.

Prehabilitation and early screening, including BIS, can ease recovery, reduce side effects and help manage lymphedema after breast cancer treatment.